First Hormone-Free Male Pill? YCT-529 Shows Early Promise

> For decades, oral contraceptive options have been limited to women, while men have had only two choices: Condoms or vasectomy. That could change with the development of YCT-529, a nonhormonal male contraceptive currently in phase 2 clinical trials, which offers a novel mechanism for inhibiting the production of viable sperm.

> YCT-529 targets retinoic acid receptor alpha, a protein critical for sperm production. “When this receptor is blocked, spermatogenesis is disrupted. In animal studies, infertility in rats was observed after 4 weeks of use, while in primates, a significant reduction in sperm production occurred within just **2 weeks**,” explained Arie Carneiro, MD, PhD

> This nonhormonal approach may improve acceptance among men. “Other male contraceptives tested previously were often combined with progesterone or testosterone blockers. Even when designed to act locally, **these compounds tend to cause sexual side effects**”.

> One of the major concerns with male contraceptives is **reversibility**, the ability to restore fertility after discontinuation. YCT-529 has shown promising results in animal studies. “In rats, normal sperm levels returned about 6 weeks after stopping the drug. In primates, recovery was observed between 2 and 3 months,” said Carneiro. This timing is in line with the natural sperm production cycle, which takes about 12 weeks to be produced and become viable